Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01278745 · ClinicalTrials.gov registry record · Phase 2
Prevention of Cardiac Allograft Vasculopathy Using Rituximab (Rituxan) Therapy in Cardiac Transplantation
A Phase 2 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Terminated
- Registry status
- Phase 2
- Development phase
- 362
- Enrollment target
NCT01278745 is a Phase 2 study that was terminated before completion, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 362 participants.
The verdict
NCT01278745, a Phase 2 study, was terminated before completion, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 362 participants
- Enrollment target
Study Summary
All people who have a heart transplant are at risk for developing cardiac allograft vasculopathy (CAV). CAV means narrowing of the heart transplant vessels, which is associated with poor heart transplant function. People who develop antibodies after transplant have a higher risk of developing CAV. Infections, high cholesterol, and rejection also increase the risk of developing CAV. People who develop CAV usually have to receive another transplant.
Interventions
- BIOLOGICAL Rituximab induction/conventional immunosuppression (tacrolimus, MMF, and steroid taper)
- DRUG Rituximab placebo/conventional immunosuppression (tacrolimus, MMF, and steroid taper)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 362 participants |
| Start Date | 2011-09 |
| Est. Completion | 2015-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01278745
The ClinicalTrials.gov registry entry for NCT01278745 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 362 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Rituximab induction/conventional immunosuppression (tacrolimus, MMF, and steroid taper) is the first listed.
NCT01278745 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01278745 about?
NCT01278745 is a clinical study titled "Prevention of Cardiac Allograft Vasculopathy Using Rituximab (Rituxan) Therapy in Cardiac Transplantation". All people who have a heart transplant are at risk for developing cardiac allograft vasculopathy (CAV). CAV means narrowing of the heart transplant vessels, which is associated with poor heart transplant function. People who develop antibodies after transplant have a higher risk of developing CAV. I...
What is the current status of trial NCT01278745?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 362 participants. The study started on 2011-09. Estimated completion is 2015-10.
What interventions are being tested in trial NCT01278745?
The interventions under investigation include: Rituximab induction/conventional immunosuppression (tacrolimus, MMF, and steroid taper) (BIOLOGICAL), Rituximab placebo/conventional immunosuppression (tacrolimus, MMF, and steroid taper) (DRUG).
Who is sponsoring clinical trial NCT01278745?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.